New antibody drug aims to halt Scleroderma's grip

NCT ID NCT05726630

Ongoing Disease control Sponsor: Biocad Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 3 trial tests whether the drug divozilimab can reduce skin thickening and protect lung function in people with systemic scleroderma, a rare autoimmune disease. About 152 adults and teens with active disease will receive either the drug or a placebo. The study is double-blind, meaning neither patients nor doctors know who gets what.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Divozilimab (a lab-made antibody that targets certain immune cells)
What this could lead to: If it works, this could offer a new treatment option to slow skin hardening and preserve lung function in people with systemic scleroderma.
What could go wrong: This is a Phase 3 trial, but results are not yet known. The drug may not improve symptoms better than placebo, and side effects from immune suppression are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLERODERMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

systemic sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SYSTEMIC SCLERODERMA

Contacts and locations

Locations

Chelyabinsk Regional Clinical hospital

Chelyabinsk, Russia
Clinical Rheumatology Hospital №25

Saint Petersburg, Russia
North-Western state Medical University named after I.I. Mechnikov

Saint Petersburg, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.